Sunovion was formed by combining Sepracor Inc. and the U.S. operations of Sumitomo Dainippon Pharma Co., Ltd.
Sepracor was founded; commercialized six products in U.S.
Sepracor was acquired by Sumitomo Dainippon, a top ten Japanese pharmaceutical company
Sepracor name is officially changed to Sunovion Pharmaceuticals Inc.
Sunovion celebrates it's five year anniversary
Sumitomo Dainippon Pharma's dedication to development. With a company history stretching back 100 years, the top-ten Tokyo-listed Sumitomo Dainippon Pharma Co., Ltd., established its foothold in the United States in 2006 as Dainippon Sumitomo Pharma America, Inc. (DSPA) and acquired Sepracor in 2009.
Now the two organizations have become one in Sunovion.
Like Sepracor, Sumitomo Dainippon Pharma has had a pragmatic approach to research, accelerating the process by tapping into a global network of partners and subsidiaries to find the most efficient and successful ways to develop and market new drugs.
Sunovion inheritance. Sunovion now brings together the scientific focus, pragmatism, and dedication to research of both Sepracor and DSPA. Our new company combines entrepreneurial energy, with the willingness to take on any challenge, and always keeping the longer view in sight.
We'll continue to develop therapies in two distinct treatment areas—central nervous system disorders and respiratory diseases, as well as explore other therapeutic areas. We will be working more and more closely with national and international partners and resources to keep a constant stream of worthwhile new drugs flowing into the pipeline. And, just as important, to keep a steady flow of effective treatments flowing out to our patients. Because we at Sunovion put our patients front and center, determined day by day to fulfill the promise of “Innovation today, healthier tomorrows.”